Kubra Kaban

Kubra Kaban

Auto-generated profile, based on publicly available information

Kubra Kaban

Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), Department of Internal Medicine, University Hospital Tübingen, 72076 Tübingen, Germany

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 May 2021 in Cancers
Verified
Journal Article
Open access
PDF file
KKKübra Kaban
Kübra Kaban
CHClemens Hinterleitner
Clemens Hinterleitner
YZYanjun Zhou
Yanjun Zhou
EŞEmine Şalva
Emine Şalva
AKAyse Gülten Kantarci
Ayse Gülten Kantarci
MMMelanie Märklin
Melanie Märklin
Overexpression of the anti-apoptotic protein BCL-2 is frequently observed in multiple malignancies, including about 85% of patients with estrogen receptor positive (ER+) breast cancer. Besides being studied as a prognostic marker, BCL-2 is investigated as a therapeutic target in ER+ breast cancer. Here, we introduce a new exosome-based strategy to target BCL-2 using genetically modified natural killer (NK) cells. The NK cell line NK92MI was lentivirally transduced to express and load BCL-2 siRNAs (siBCL-2) into exosomes (NKExos) and then evaluated for its potential to treat ER+ breast cancer. Transfected NK92MI cells produced substantial levels of BCL-2 siRNAs, without substantially affecting NK cell viability or effector function and led to loading of siBCL-2 in NKExos. Remarkably, targeting BCL-2 via siBCL-2 NKExos led to enhanced intrinsic apoptosis in breast cancer cells, without affecting non-malignant cells. Together, our prototypical results for BCL-2 in breast cancer provide proof of concept for a novel strategy to utilize NKExos as a natural delivery vector for siRNA targeting of oncogenes.

20 October 2016 in Nucleic Acid Therapeutics
Verified
Journal Article
Closed access
KKKubra Kaban
Kubra Kaban
ESEmine Salva
Emine Salva
FAFatma JULIDE AKBUGA
Fatma JULIDE AKBUGA
Changes in microRNA (miRNA) expression levels that play important roles in regulation lead to many pathological events such as cancer. The miR-200 family is an important target in cancer therapy. The aim of this study is to equilibrate endogenous levels between cancer and noncancerous cells to prevent serious side effects of miR-200c- and miR-141-like metastatic colonization. For the first time, the characterization of miR-200c and miR-141 cluster containing chitosan nanoplexes was shown, and the optimization of miRNA expression levels by conducting dose studies in breast cancer cell lines was made. The mean diameter of chitosan/miR-141 and chitosan/miR-200c nanoplexes ranged from 296 to 355 nm and from 294 to 380 nm depending on the N/P ratio, respectively. The surface charge of nanoplexes was positive with zeta potential of +12 to +26 mV. While naked miRNA was degraded after 0 min in a 10% serum-containing medium, chitosan/miRNA nanoplexes were protected for 72 h. During the in vitro cellular uptake study, nanoplexes were observed to be accumulating in the cytoplasm or nucleus. After using different doses for miR-200c, the determined doses are 750, 100, and 750 ng in the MCF-7, MDA-MB-231, and MDA-MB-435 cell lines, respectively. Doses were determined as 100 ng for MDA-MB-231 and 150 ng for MDA-MB-435 to reach endogenous miR-141 levels of MCF-10A. Our results suggest that chitosan nanoplexes for miR-200c and miR-141 are an efficient delivery system in terms of formulation and transfection. As a conclusion, dose studies are important to provide effective treatment with miRNAs.

1 December 2016 in European Journal of Pharmaceutical Sciences
Verified
Journal Article
Closed access
KKKubra Kaban
Kubra Kaban
ESEmine Salva
Emine Salva
FAFatma JULIDE AKBUGA
Fatma JULIDE AKBUGA

7 August 2019 in The Journal of Gene Medicine
Verified
Journal Article
Closed access
PDF file
KKKubra Kaban
Kubra Kaban
EŞEmine Şalva
Emine Şalva
FAFatma JULIDE AKBUGA
Fatma JULIDE AKBUGA

4 November 2021 in Diagnostics
Verified
Journal Article
Open access
PDF file
KKKübra Kaban
Kübra Kaban
SGSarah Maria Greiner
Sarah Maria Greiner
SHSamuel J. Holzmayer
Samuel J. Holzmayer
CTClaudia Tandler
Claudia Tandler
SMSophie Meyer
Sophie Meyer
JHJonas S. Heitmann
Jonas S. Heitmann
Recent success of novel therapies has improved treatment of chronic lymphocytic leukemia (CLL) patients, but most of them still require several treatment regimes. To improve treatment choice, prognostic markers suitable for prediction of disease outcome are required. Several molecular/genetic markers have been established, but accessibility for the entirety of all patients is limited. We here evaluated the relevance of GITR/4-1BB as well as their ligands for the prognosis of CLL patients. Surface expression of GITR/GITRL and 4-1BB/4-1BBL was correlated with established prognostic markers. Next, we separated our patient population according to GITR/GITRL and 4-1BB/4-1BBL expression in groups with high/low expression levels and performed Kaplan-Meier analyses. Interestingly, no correlation was observed with the defined prognostic markers. Whereas no significant difference between high and low expression of GITR, GITRL and 4-1BBL was observed, high 4-1BB levels on leukemic cells were associated with significantly shorter survival. Thereby we identify 4-1BB as prognostic marker for CLL.